Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives $22.22 Consensus PT from Brokerages

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) have been given a consensus rating of “Moderate Buy” by the ten analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $22.2222.

Several research analysts recently issued reports on BCYC shares. JMP Securities dropped their price objective on Bicycle Therapeutics from $22.00 to $10.00 and set a “market outperform” rating on the stock in a research note on Tuesday, August 12th. Morgan Stanley dropped their price objective on Bicycle Therapeutics from $17.00 to $13.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 12th. Royal Bank Of Canada set a $27.00 price objective on Bicycle Therapeutics and gave the stock an “outperform” rating in a research note on Monday, August 11th. Oppenheimer reiterated an “outperform” rating and issued a $44.00 price target (down from $48.00) on shares of Bicycle Therapeutics in a report on Monday, August 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicycle Therapeutics in a report on Tuesday, October 14th.

Bicycle Therapeutics Stock Down 5.5%

Shares of NASDAQ:BCYC opened at $8.17 on Friday. Bicycle Therapeutics has a 52-week low of $6.10 and a 52-week high of $27.70. The stock has a market cap of $566.24 million, a P/E ratio of -2.33 and a beta of 1.47. The business’s 50 day moving average is $7.49 and its 200 day moving average is $7.78.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings data on Friday, August 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by ($0.19). Bicycle Therapeutics had a negative return on equity of 32.43% and a negative net margin of 1,257.00%.The firm had revenue of $2.90 million during the quarter, compared to the consensus estimate of $9.43 million. On average, sell-side analysts anticipate that Bicycle Therapeutics will post -3.06 EPS for the current fiscal year.

Insider Activity

In other news, CEO Kevin Lee sold 3,231 shares of Bicycle Therapeutics stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $8.41, for a total value of $27,172.71. Following the transaction, the chief executive officer directly owned 475,310 shares in the company, valued at approximately $3,997,357.10. This trade represents a 0.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders sold 8,527 shares of company stock valued at $71,738. Company insiders own 22.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in BCYC. Ausdal Financial Partners Inc. purchased a new position in shares of Bicycle Therapeutics in the 2nd quarter valued at $70,000. Sei Investments Co. acquired a new stake in shares of Bicycle Therapeutics in the 2nd quarter worth $74,000. Virtus Investment Advisers LLC boosted its position in shares of Bicycle Therapeutics by 32.6% in the 2nd quarter. Virtus Investment Advisers LLC now owns 10,821 shares of the company’s stock worth $75,000 after purchasing an additional 2,659 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Bicycle Therapeutics by 879.5% in the 1st quarter. GAMMA Investing LLC now owns 8,982 shares of the company’s stock worth $76,000 after purchasing an additional 8,065 shares in the last quarter. Finally, Ameriprise Financial Inc. acquired a new stake in shares of Bicycle Therapeutics in the 2nd quarter worth $86,000. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.